O	0	6	Impact
O	7	9	of
B-intervention	10	18	pectoral
I-intervention	19	24	nerve
I-intervention	25	30	block
O	31	33	on
B-condition	34	47	postoperative
I-condition	48	52	pain
O	53	56	and
O	57	64	quality
O	65	67	of
O	68	76	recovery
O	77	79	in
O	80	88	patients
O	89	99	undergoing
O	100	106	breast
O	107	113	cancer
O	114	121	surgery
O	121	122	:
O	123	124	A
O	125	135	randomised
O	136	146	controlled
O	147	152	trial
O	152	153	.

O	154	156	In
O	157	163	recent
O	164	169	years
O	169	170	,
O	171	179	thoracic
O	180	184	wall
O	185	190	nerve
O	191	197	blocks
O	197	198	,
O	199	203	such
O	204	206	as
O	207	210	the
O	211	219	pectoral
O	220	225	nerve
O	226	227	(
O	227	231	PECS
O	231	232	)
O	233	238	block
O	239	242	and
O	243	246	the
O	247	255	serratus
O	256	261	plane
O	262	267	block
O	268	272	have
O	273	279	become
O	280	287	popular
O	288	291	for
O	292	296	peri
O	296	297	-
O	297	306	operative
O	307	311	pain
O	312	319	control
O	320	322	in
O	323	331	patients
O	332	342	undergoing
O	343	349	breast
O	350	356	cancer
O	357	364	surgery
O	364	365	.

O	366	369	The
O	370	376	effect
O	377	379	of
O	380	384	PECS
O	385	390	block
O	391	393	on
O	394	401	quality
O	402	404	of
O	405	413	recovery
O	414	415	(
O	415	418	QoR
O	418	419	)
O	420	425	after
O	426	432	breast
O	433	439	cancer
O	440	447	surgery
O	448	451	has
O	452	455	not
O	456	460	been
O	461	470	evaluated
O	470	471	.

O	472	474	To
O	475	483	evaluate
O	484	487	the
O	488	495	ability
O	496	498	of
O	499	503	PECS
O	504	509	block
O	510	512	to
O	513	521	decrease
O	522	535	postoperative
O	536	540	pain
O	541	544	and
O	545	556	anaesthesia
O	557	560	and
O	561	570	analgesia
O	571	583	requirements
O	584	587	and
O	588	590	to
O	591	598	improve
O	599	612	postoperative
O	613	616	QoR
O	617	619	in
O	620	628	patients
O	629	639	undergoing
O	640	646	breast
O	647	653	cancer
O	654	661	surgery
O	661	662	.

O	663	673	Randomised
O	674	684	controlled
O	685	690	study
O	690	691	.

O	692	693	A
O	694	702	tertiary
O	703	711	hospital
O	711	712	.

B-total-participants	713	718	Sixty
B-eligibility	719	724	women
I-eligibility	725	735	undergoing
I-eligibility	736	742	breast
I-eligibility	743	749	cancer
I-eligibility	750	757	surgery
O	758	765	between
O	766	771	April
O	772	776	2014
O	777	780	and
O	781	789	February
O	790	794	2015
O	794	795	.

O	796	799	The
O	800	808	patients
O	809	813	were
O	814	824	randomised
O	825	827	to
O	828	835	receive
O	836	837	a
O	838	842	PECS
O	843	848	block
O	849	859	consisting
O	860	862	of
O	863	865	30
O	866	868	ml
O	869	871	of
O	872	887	levobupivacaine
O	888	889	0
O	889	890	.
O	890	892	25
O	892	893	%
O	894	899	after
O	900	909	induction
O	910	912	of
O	913	924	anaesthesia
O	925	926	(
O	926	930	PECS
O	931	936	group
O	936	937	)
O	938	940	or
O	941	942	a
B-control	943	949	saline
I-control	950	954	mock
I-control	955	960	block
I-control	961	962	(
I-control	962	969	control
I-control	970	975	group
I-control	975	976	)
O	976	977	.

O	978	981	The
O	982	990	patients
O	991	999	answered
O	1000	1001	a
O	1002	1004	40
O	1004	1005	-
O	1005	1009	item
O	1010	1013	QoR
O	1014	1027	questionnaire
O	1028	1029	(
O	1029	1032	QoR
O	1032	1033	-
O	1033	1035	40
O	1035	1036	)
O	1037	1043	before
O	1044	1047	and
O	1048	1049	1
O	1050	1053	day
O	1054	1059	after
O	1060	1066	breast
O	1067	1073	cancer
O	1074	1081	surgery
O	1081	1082	.

O	1083	1090	Numeric
O	1091	1097	Rating
O	1098	1103	Scale
O	1104	1109	score
O	1110	1113	for
O	1114	1127	postoperative
O	1128	1132	pain
O	1132	1133	,
O	1134	1145	requirement
O	1146	1149	for
O	1150	1155	intra
O	1155	1156	-
O	1156	1165	operative
O	1166	1174	propofol
O	1175	1178	and
O	1179	1191	remifentanil
O	1191	1192	,
O	1193	1196	and
O	1197	1200	QoR
O	1200	1201	-
O	1201	1203	40
O	1204	1209	score
O	1210	1212	on
O	1213	1226	postoperative
O	1227	1230	day
O	1231	1232	1
O	1232	1233	.

O	1234	1238	PECS
O	1239	1244	block
O	1245	1253	combined
O	1254	1258	with
O	1259	1267	propofol
O	1267	1268	-
O	1268	1280	remifentanil
O	1281	1292	anaesthesia
O	1293	1306	significantly
O	1307	1315	improved
O	1316	1319	the
O	1320	1326	median
O	1327	1328	[
O	1328	1341	interquartile
O	1342	1347	range
O	1347	1348	]
B-outcome	1349	1353	pain
I-outcome	1354	1359	score
I-outcome	1360	1362	at
I-outcome	1363	1364	6
I-outcome	1365	1366	h
I-outcome	1367	1382	postoperatively
O	1383	1384	(
O	1384	1388	PECS
O	1389	1394	group
B-iv-cont-median	1395	1396	1
O	1397	1398	[
O	1398	1399	0
O	1400	1402	to
O	1403	1404	2
O	1404	1405	]
O	1406	1408	vs
O	1408	1409	.
O	1410	1417	Control
O	1418	1423	group
B-cv-cont-median	1424	1425	1
O	1426	1427	[
O	1427	1428	0
O	1428	1429	.
O	1429	1431	25
O	1432	1434	to
O	1435	1436	2
O	1436	1437	.
O	1437	1439	75
O	1439	1440	]
O	1440	1441	;
O	1442	1443	P
O	1444	1445	=
O	1446	1447	0
O	1447	1448	.
O	1448	1451	018
O	1451	1452	]
O	1452	1453	.

O	1454	1458	PECS
O	1459	1464	block
O	1465	1469	also
O	1470	1477	reduced
O	1478	1486	propofol
O	1487	1491	mean
O	1492	1493	(
O	1493	1494	±
O	1495	1497	SD
O	1497	1498	)
O	1499	1508	estimated
O	1509	1515	target
B-outcome	1516	1521	blood
I-outcome	1522	1535	concentration
I-outcome	1536	1538	to
I-outcome	1539	1547	maintain
I-outcome	1548	1558	bispectral
I-outcome	1559	1564	index
I-outcome	1565	1566	(
I-outcome	1566	1569	BIS
I-outcome	1569	1570	)
I-outcome	1571	1578	between
I-outcome	1579	1581	40
I-outcome	1582	1585	and
I-outcome	1586	1588	50
O	1589	1590	(
O	1590	1594	PECS
O	1595	1600	group
B-iv-cont-mean	1601	1602	2
I-iv-cont-mean	1602	1603	.
I-iv-cont-mean	1603	1605	65
O	1606	1607	(
O	1607	1608	±
B-iv-cont-sd	1609	1610	0
I-iv-cont-sd	1610	1611	.
I-iv-cont-sd	1611	1613	52
O	1613	1614	)
O	1615	1617	vs
O	1617	1618	.
O	1619	1626	Control
O	1627	1632	group
B-cv-cont-mean	1633	1634	3
I-cv-cont-mean	1634	1635	.
I-cv-cont-mean	1635	1637	08
O	1638	1639	(
O	1639	1640	±
B-cv-cont-sd	1641	1642	0
I-cv-cont-sd	1642	1643	.
I-cv-cont-sd	1643	1645	41
O	1645	1646	)
O	1647	1648	μ
O	1648	1649	g
O	1650	1652	ml
O	1652	1653	;
O	1654	1655	P
O	1656	1657	<
O	1658	1659	0
O	1659	1660	.
O	1660	1663	001
O	1663	1664	)
O	1665	1668	but
O	1669	1672	not
B-outcome	1673	1685	remifentanil
I-outcome	1686	1697	consumption
O	1698	1699	(
O	1699	1703	PECS
O	1704	1709	group
B-iv-cont-mean	1710	1712	10
I-iv-cont-mean	1712	1713	.
I-iv-cont-mean	1713	1714	5
O	1715	1716	(
O	1716	1717	±
B-iv-cont-sd	1718	1719	4
I-iv-cont-sd	1719	1720	.
I-iv-cont-sd	1720	1722	28
O	1722	1723	)
O	1724	1726	vs
O	1726	1727	.
O	1728	1735	Control
O	1736	1741	group
B-cv-cont-mean	1742	1744	10
I-cv-cont-mean	1744	1745	.
I-cv-cont-mean	1745	1746	4
O	1747	1748	(
O	1748	1749	±
B-cv-cont-sd	1750	1751	4
I-cv-cont-sd	1751	1752	.
I-cv-cont-sd	1752	1754	68
O	1754	1755	)
O	1756	1757	μ
O	1757	1758	g
O	1759	1761	kg
O	1762	1763	h
O	1763	1764	;
O	1765	1766	P
O	1767	1768	=
O	1769	1770	0
O	1770	1771	.
O	1771	1773	95
O	1773	1774	)
O	1774	1775	.

O	1776	1780	PECS
O	1781	1786	block
O	1787	1790	did
O	1791	1794	not
O	1795	1802	improve
O	1803	1806	the
B-outcome	1807	1810	QoR
I-outcome	1810	1811	-
I-outcome	1811	1813	40
I-outcome	1814	1819	score
I-outcome	1820	1822	on
I-outcome	1823	1836	postoperative
I-outcome	1837	1840	day
I-outcome	1841	1842	1
O	1843	1844	(
O	1844	1848	PECS
O	1849	1854	group
B-iv-cont-median	1855	1858	182
O	1859	1860	[
O	1860	1863	176
O	1864	1866	to
O	1867	1870	189
O	1870	1871	]
O	1872	1874	vs
O	1874	1875	.
O	1876	1883	Control
O	1884	1889	group
B-cv-cont-median	1890	1893	174
I-cv-cont-median	1893	1894	.
I-cv-cont-median	1894	1895	5
O	1896	1897	[
O	1897	1900	157
O	1900	1901	.
O	1901	1903	75
O	1904	1906	to
O	1907	1910	175
O	1910	1911	]
O	1911	1912	)
O	1912	1913	.

O	1914	1916	In
O	1917	1925	patients
O	1926	1936	undergoing
O	1937	1943	breast
O	1944	1950	cancer
O	1951	1958	surgery
O	1958	1959	,
O	1960	1964	PECS
O	1965	1970	block
O	1971	1979	combined
O	1980	1984	with
O	1985	1992	general
O	1993	2004	anaesthesia
O	2005	2012	reduced
O	2013	2016	the
O	2017	2028	requirement
O	2029	2032	for
O	2033	2041	propofol
O	2042	2045	but
O	2046	2049	not
O	2050	2054	that
O	2055	2058	for
O	2059	2071	remifentanil
O	2071	2072	,
O	2073	2076	due
O	2077	2079	to
O	2080	2083	the
O	2084	2093	inability
O	2094	2096	of
O	2097	2100	the
O	2101	2105	PECS
O	2106	2111	block
O	2112	2114	to
O	2115	2120	reach
O	2121	2124	the
O	2125	2133	internal
O	2134	2141	mammary
O	2142	2146	area
O	2146	2147	.

O	2148	2155	Further
O	2155	2156	,
O	2157	2161	PECS
O	2162	2167	block
O	2168	2176	improved
B-outcome	2177	2190	postoperative
I-outcome	2191	2195	pain
O	2196	2199	but
O	2200	2203	not
O	2204	2207	the
O	2208	2221	postoperative
O	2222	2225	QoR
O	2225	2226	-
O	2226	2228	40
O	2229	2234	score
O	2235	2238	due
O	2239	2241	to
O	2242	2245	the
O	2246	2253	factors
O	2254	2258	that
O	2259	2265	cannot
O	2266	2268	be
O	2269	2277	measured
O	2278	2280	by
O	2281	2290	analgesia
O	2291	2302	immediately
O	2303	2308	after
O	2309	2316	surgery
O	2316	2317	,
O	2318	2322	such
O	2323	2325	as
O	2326	2333	rebound
O	2334	2338	pain
O	2338	2339	.

O	2340	2344	This
O	2345	2350	trial
O	2351	2353	is
O	2354	2364	registered
O	2365	2369	with
O	2370	2373	the
O	2374	2384	University
O	2385	2393	Hospital
O	2394	2401	Medical
O	2402	2413	Information
O	2414	2421	Network
O	2422	2430	Clinical
O	2431	2437	Trials
O	2438	2446	Registry
O	2447	2448	(
O	2448	2461	UMIN000013435
O	2461	2462	)
O	2462	2463	.
